These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 28721500

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
    Chen YF, Yuan A, Cho KH, Lu YC, Kuo MY, Chen JH, Chang YC.
    PLoS One; 2017; 12(11):e0187824. PubMed ID: 29121075
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Contrast-enhanced ultrasound evaluation of pancreatic cancer xenografts in nude mice after irradiation with sub-threshold focused ultrasound for tumor ablation.
    Gao YH, Wu L, Wang R, Guo Q, Chen YN, Hu B, Jiang LX.
    Oncotarget; 2017 Jun 06; 8(23):37584-37593. PubMed ID: 28402267
    [Abstract] [Full Text] [Related]

  • 27. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
    Helbert A, Von Wronski M, Colevret D, Botteron C, Padilla F, Bettinger T, Tardy I, Hyvelin JM.
    Invest Radiol; 2020 Oct 06; 55(10):657-665. PubMed ID: 32229739
    [Abstract] [Full Text] [Related]

  • 28. DCE-MRI and Quantitative Histology Reveal Enhanced Vessel Maturation but Impaired Perfusion and Increased Hypoxia in Bevacizumab-Treated Cervical Carcinoma.
    Hauge A, Gaustad JV, Huang R, Simonsen TG, Wegner CS, Andersen LMK, Rofstad EK.
    Int J Radiat Oncol Biol Phys; 2019 Jul 01; 104(3):666-676. PubMed ID: 30858145
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.
    Malamas AS, Jin E, Zhang Q, Haaga J, Lu ZR.
    Pharm Res; 2015 Sep 01; 32(9):3029-43. PubMed ID: 25840948
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.
    Piludu F, Marzi S, Pace A, Villani V, Fabi A, Carapella CM, Terrenato I, Antenucci A, Vidiri A.
    Neuroradiology; 2015 Dec 01; 57(12):1269-80. PubMed ID: 26364181
    [Abstract] [Full Text] [Related]

  • 33. Standardization of dynamic contrast-enhanced ultrasound for the evaluation of antiangiogenic therapies: the French multicenter Support for Innovative and Expensive Techniques Study.
    Lassau N, Chapotot L, Benatsou B, Vilgrain V, Kind M, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Uzan-Augui J, Koscielny S.
    Invest Radiol; 2012 Dec 01; 47(12):711-6. PubMed ID: 23095862
    [Abstract] [Full Text] [Related]

  • 34. Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy.
    Sorace AG, Saini R, Mahoney M, Hoyt K.
    J Ultrasound Med; 2012 Oct 01; 31(10):1543-50. PubMed ID: 23011617
    [Abstract] [Full Text] [Related]

  • 35. Contrast-enhanced ultrasound with perflubutane in the assessment of anti-angiogenic effects: early prediction of the anticancer activity of bevacizumab in a mouse xenografted model.
    Watanabe R, Munemasa T, Matsumura M.
    Ultrasound Med Biol; 2015 Sep 01; 41(9):2497-505. PubMed ID: 26022792
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Dynamic contrast-enhanced micro-CT on mice with mammary carcinoma for the assessment of antiangiogenic therapy response.
    Eisa F, Brauweiler R, Hupfer M, Nowak T, Lotz L, Hoffmann I, Wachter D, Dittrich R, Beckmann MW, Jost G, Pietsch H, Kalender WA.
    Eur Radiol; 2012 Apr 01; 22(4):900-7. PubMed ID: 22071777
    [Abstract] [Full Text] [Related]

  • 39. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
    Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS.
    J Magn Reson Imaging; 2013 Nov 01; 38(5):1043-53. PubMed ID: 23908122
    [Abstract] [Full Text] [Related]

  • 40. Contrast-enhanced ultrasonic parametric perfusion imaging in the evaluation of antiangiogenic tumor treatment.
    Zhou JH, Zheng W, Cao LH, Liu M, Luo RZ, Han F, Wu PH, Li AH.
    Eur J Radiol; 2012 Jun 01; 81(6):1360-5. PubMed ID: 21345633
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.